Security
LGVN · Longeveron Inc.
LGVNNASDAQCommon stockCurrentCIK 1721484Updated Sep 27, 2026
Name history
LONGEVERON LLC · through Feb 10, 2021
LGVN price & chart
Loading TradingView…
NASDAQ:LGVN on TradingView ↗About the company
We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®.
In the news
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01
SCHEDULE 13G filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 5.03, 7.01, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,261,000Source | 25,558,000Source | 12,078,000Source | 27,413,000Source |
| Property, Plant and Equipment, NetUSD | 1,836,000Source | 2,449,000Source | 2,529,000Source | 2,949,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,285,000Source | 2,401,000Source | 2,287,000Source | 2,409,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,661,000Source | 19,232,000Source | 4,949,000Source | 10,503,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 104,000Source | 84,000Source | 111,000Source | 218,000Source |
| Assets, CurrentUSD | 5,451,000Source | 19,624,000Source | 5,848,000Source | 20,280,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 686,000Source | 308,000Source | 376,000Source | 404,000Source |
| Operating Lease, Right-of-Use AssetUSD | 513,000Source | 882,000Source | 1,221,000Source | 1,531,000Source |
| Other Assets, NoncurrentUSD | 176,000Source | 202,000Source | 193,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,586,000Source | 3,671,000Source | 5,337,000Source | 6,910,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | — | — | — | 6,000Source |
| Additional Paid in CapitalUSD | 137,964,000Source | 131,480,000Source | 91,800,000Source | 83,712,000Source |
| Retained Earnings (Accumulated Deficit)USD | -132,311,000Source | -109,607,000Source | -84,984,000Source | -62,773,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | -357,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,675,000Source | 21,887,000Source | 6,741,000Source | 20,503,000Source |
| Liabilities and EquityUSD | 10,261,000Source | 25,558,000Source | 12,078,000Source | 27,413,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,087,000Source | 2,582,000Source | 3,889,000Source | 4,869,000Source |
| Operating Lease, Liability, CurrentUSD | 655,000Source | 623,000Source | 593,000Source | — |
| Accounts Payable, CurrentUSD | 423,000Source | 99,000Source | 638,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 169,000Source | 824,000Source | 1,448,000Source | — |
| Other Liabilities, NoncurrentUSD | 330,000Source | 265,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,969,000Source | 1,820,000Source | 2,152,000Source | 650,000Source |
| Deferred Revenue, CurrentUSD | — | — | 506,000Source | 506,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 800,000Source | 700,000Source | 700,000Source | 0.7Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,677,000Source | 2,328,000Source | 2,032,000Source | 170,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 325,000Source | -540,000Source | -1,113,000Source | 1,106,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -18,645,000Source | -13,868,000Source | -19,002,000Source | -13,969,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -595,000Source | -640,000Source | 8,186,000Source | -677,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 245,000Source | 655,000Source | 301,000Source | 569,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | 174,000Source | 304,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,669,000Source | 28,791,000Source | 5,262,000Source | -509,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,661,000Source | 19,232,000Source | 4,949,000Source | 10,503,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,000,000Source | 2,300,000Source |
| Amortization of Intangible AssetsUSD | 400,000Source | 200,000Source | 200,000Source | 200,000Source |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | 893,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -97,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -97,000Source | — | — | — |
| General and Administrative ExpenseUSD | 12,049,000Source | 10,269,000Source | 11,401,000Source | 8,119,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -18,835,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | -179,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | 0Source | 0Source | 357,334,000Source |
| Net Income (Loss) Attributable to ParentUSD | -22,704,000Source | -15,973,000Source | -21,413,000Source | -18,835,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -22,704,000Source | -24,623,000Source | -22,211,000Source | — |
| Nonoperating Income (Expense)USD | 583,000Source | 549,000Source | -384,000Source | — |
| Operating ExpensesUSD | 24,090,000Source | 18,406,000Source | 21,250,000Source | 18,540,000Source |
| Other Nonoperating Income (Expense)USD | 680,000Source | 549,000Source | -377,000Source | -792,000Source |
| Proceeds from Issuance of Common StockUSD | 4,980,000Source | 12,866,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 2,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 940,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 3,000,000Source | 3,000,000Source | 3,000,000Source | 2,900,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | 0Source | -300,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,199,000Source | 2,392,000Source | 709,000Source | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -23,287,000Source | -16,522,000Source | -21,029,000Source | -18,043,000Source |
| Other Nonoperating Income (Expense)USD | 680,000Source | 549,000Source | -377,000Source | -792,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -22,704,000Source | -15,973,000Source | -21,413,000Source | -18,835,000Source |
| Earnings Per Share, BasicUSD per share | -1.29Source | -2.62Source | -1.02Source | -0.9Source |
| Earnings Per Share, DilutedUSD per share | -1.29Source | -2.62Source | -1.02Source | -0.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 17,576,551,000Source | 9,411,164,000Source | 21,734,901Source | 20,969,032Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 17,576,551,000Source | 9,411,164,000Source | 21,734,901Source | 20,969,032Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 400,000Source | 200,000Source | 200,000Source | 200,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,226,000Source | 958,000Source | 946,000Source | — |
| General and Administrative ExpenseUSD | 12,049,000Source | 10,269,000Source | 11,401,000Source | 8,119,000Source |
| Gross ProfitUSD | 803,000Source | 1,884,000Source | 221,000Source | 497,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -18,835,000Source |
| Interest ExpenseUSD | — | — | — | 1,398,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -22,704,000Source | -24,623,000Source | -22,211,000Source | — |
| Nonoperating Income (Expense)USD | 583,000Source | 549,000Source | -384,000Source | — |
| Operating ExpensesUSD | 24,090,000Source | 18,406,000Source | 21,250,000Source | 18,540,000Source |
| Other IncomeUSD | — | — | — | 300,000Source |
| Research and Development ExpenseUSD | 12,041,000Source | 8,137,000Source | 9,066,000Source | 9,370,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 940,000Source |
| Selling and Marketing ExpenseUSD | — | — | 783,000Source | 1,051,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 3,000,000Source | 3,000,000Source | 3,000,000Source | 2,900,000Source |
Offerings
Registration 333-294975
Filing attachments
ea030614701ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) ------------------- Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the…
Read attachment ↗ea030309701ex99-1.htm · 8-K · 2026-08-24
EX-99.1 3 ea030309701ex99-1.htm PRESS RELEASE DATED AUGUST 24, 2026 Exhibit 99.1 Longeveron Announces 1-for-10 Reverse Stock Split MIAMI, Fla., August 24, 2026 - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common …
Read attachment ↗ea030272301ex99-1.htm · 8-K · 2026-08-19
EX-99.1 3 ea030272301ex99-1.htm PRESS RELEASE Exhibit 99.1 Longeveron Appoints Nirav Jhaveri as Chief Financial Officer Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Fla., August 19, 2026 -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-rela…
Read attachment ↗ea030175701ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ea030175701ex99-1.htm PRESS RELEASE ISSUED BY THE COMPANY ON AUGUST 12, 2026 Exhibit 99.1 Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication ────────────────────────────────────────────────────…
Read attachment ↗ea029715301ex99-1.htm · 8-K · 2026-07-06
EX-99.1 3 ea029715301ex99-1.htm PRESS RELEASE DATED JULY 6, 2026 Exhibit 99.1 Longeveron® Appoints Marie Washburn as Chief Financial Officer Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 ─────────────────────────────────────…
Read attachment ↗ea029043601ex99-1.htm · 8-K · 2026-05-13
EX-99.1 2 ea029043601ex99-1.htm PRESS RELEASE ISSUED BY THE COMPANY ON MAY 13, 2026 Exhibit 99.1 Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indication ────────────────────────────────────────────────────────────────────…
Read attachment ↗